Ropivacaine
- Generic Name
- Ropivacaine
- Brand Names
- Naropin
- Drug Type
- Small Molecule
- Chemical Formula
- C17H26N2O
- CAS Number
- 84057-95-4
- Unique Ingredient Identifier
- 7IO5LYA57N
- Background
Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
- Indication
Ropivacaine is indicated in adult patients for the induction of regional or local anesthesia for surgery or acute pain management.
- Associated Conditions
- Acute Pain, Postoperative pain
- Associated Therapies
- Surgical anesthesia therapy
Pre vs Post Block in Total Knee Arthroplasty (TKA)
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 84
- Registration Number
- NCT05974501
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Liposomal Bupivacaine/Bupivacaine in RS Blocks vs. Ropivacaine in RS Blocks And Catheters
- Conditions
- Interventions
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Hartford Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05972018
- Locations
- 🇺🇸
Hartford Hospital, Hartford, Connecticut, United States
Effect of Quadratus Lumborum Block With Compound Lidocaine and Esketamine on Pain After Colorectal Surgery
- Conditions
- Interventions
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Tianjin Medical University General Hospital
- Target Recruit Count
- 160
- Registration Number
- NCT05964985
Analgesic Effects of Caudal S-ketamine for Supplementation of Ropivacaine Caudal Analgesia in Children With Hypospadias
- Conditions
- Interventions
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Tao Zhang
- Target Recruit Count
- 44
- Registration Number
- NCT05922605
- Locations
- 🇨🇳
First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Effect of Epidural Hydromorphone Combined With Ropivacaine in Labor Analgesia
- Conditions
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2023-06-13
- Target Recruit Count
- 240
- Registration Number
- NCT05901441
- Locations
- 🇨🇳
Maternal and Child Health Hospital of Hubei Province, Wuhan, Hubei, China
Dexmedetomidine Ropivacaine Versus Plain Ropivacaine in Bilateral Pectoralis Nerve Block
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Fayoum University Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT05897307
- Locations
- 🇸🇦
King Saud University, Riyadh, Saudi Arabia
Evaluate Efficacy Levobupivacaine 0.125% Versuss Ropivacaine 0.2% in Hemodynamic Alterations in Labor and Fetal Repercussions
- Conditions
- Interventions
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2023-05-26
- Target Recruit Count
- 40
- Registration Number
- NCT05877131
- Locations
- 🇪🇸
Althaia Xarxa Assitensial i Universitaria Manresa, Manresa, Barcelona, Spain
Paravertebral Block vs no Block in Open Pancreaticoduodenectomy
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 40
- Registration Number
- NCT05820997
- Locations
- 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
A Study to Evaluate Analgesic Efficacy and Safety of PRF-110 for Post-surgical Pain
- First Posted Date
- 2023-03-17
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- PainReform LTD
- Target Recruit Count
- 415
- Registration Number
- NCT05773846
- Locations
- 🇺🇸
Woodland International Research Group, Little Rock, Arkansas, United States
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸Midwest Clinical Research Center, Dayton, Ohio, United States
A Study of HR18034 for Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy
- Conditions
- Interventions
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 294
- Registration Number
- NCT05769855
- Locations
- 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.